How to Buy Nurix Therapeutics Stock
Nurix Therapeutics Inc
Nurix Therapeutics, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases.
Nurix Therapeutics stock last closed at $23.21, down 1.57% from the previous day, and has increased 106.13% in one year. It has overperformed other stocks in the Biotechnology industry by 1.19 percentage points. Nurix Therapeutics stock is currently +183.22% from its 52-week low of $8.20, and -7.46% from its 52-week high of $25.08.
There are currently 103.78M shares of NRIX outstanding. The market capitalization of NRIX is $2.41B. In the last 24 hours, 752,000 NRIX shares were traded.
How to Buy Nurix Therapeutics Stock
Wondering how to invest in Nurix Therapeutics stock? Here's how.
- Decide where to buy Nurix Therapeutics stock: You need to decide on a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you figure out where to buy Nurix Therapeutics stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Pick your method of payment and add your information.
- Research Nurix Therapeutics stock: The Nurix Therapeutics ticker symbol is NRIX. Is Nurix Therapeutics stock a good investment? Should you buy shares of NRIX? How do NRIX's underlying business fundamentals look? Do top analysts think Nurix Therapeutics is a good buy? Why has NRIX's stock price moved recently? (Hint: Our stock research website can help you figure out if NRIX is a good stock to buy).
- Place your NRIX purchase: Decide if you will purchase NRIX shares at the current market price or use a limit order to purchase NRIX stock at a given price.
- Get updates on your investment in NRIX: Create a watchlist to important notifications about your investment in Nurix Therapeutics shares.
Step 1: Decide where to buy Nurix Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy NRIX shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Tech to Healthcare, New York to Hong Kong (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
- Social investing: eToro boasts a community of more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by opening an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create a brokerage account
Now that you've picked your brokerage, you'll need to fill out some personal details so you can invest in NRIX today.
How to Start a New Investment Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create a new trading account.
- Send your details by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've filled out your info on app for investing, your next step is to transfer the money for your investment:
Check out the video below to see the process of depositing funds into your new investment account.
Step 4: Research Nurix Therapeutics stock
After you have decided on the best place to buy Nurix Therapeutics stock, it's critical to research their stock prior to investing, so you truly comprehend the risk as well as the opportunity.
Nurix Therapeutics shares at a glance
Nurix Therapeutics Due Diligence Checks
WallStreetZen was built to help average investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on NRIX's stock page.
What is the fair value of NRIX stock?
Analysts use many financial metrics, analyses, models, and charts to gauge NRIX's fair value.
Using relative valuations ratios:
- NRIX may be overvalued based on its P/B ratio of 5.98x, relative to Biotechnology industry P/B ratio of 5.23x
You can do additional valuation analysis on NRIX's stock here.
NRIX Financials at a glance
Positive Health Checks:
- There are more short-term assets than short-term liabilities on the NRIX balance sheet.
- NRIX has cash burn of 304527000. It has sufficient cash and short-term investments to cover this for at least one year.
- NRIX has a low debt to equity ratio of 0.33.
- There are more short-term assets than long-term liabilities on the NRIX balance sheet.
Negative Health Checks:
- NRIX has $444.50M in cash and short term investments. This is not enough to cover its annual cash burn of $304.53M.
- Total NRIX debt is higher than 5 years ago, relative to shareholder equity.
- NRIX profit margin has gone down from -234.6% to -928.4% in the past year.
Do Wall Street analysts think it's a good time to buy Nurix Therapeutics stock
Out of 12 Wall Street analysts who give forecasts on NRIX, the consensus analyst rating on Nurix Therapeutics is a Strong Buy
Please note that analyst ratings are not stock recommendations, nor are they financial advice.
Latest NRIX Analyst Forecasts
Stephen Willey, a top 24% analyst from Stifel Nicolaus maintains NRIX with a strong buy rating and raises their NRIX price target from $34.00 to $40.00, on Jul 10, 2026.
Stifel Nicolaus's Stephen Willey raised their price target on Nurix Therapeutics (NASDAQ: NRIX) by 17.6% from $34 to $40 on 2026/07/10. The analyst maintained their Strong Buy rating on the stock.
Nurix Therapeutics reported its Q2 2026 earnings.
Raising their price target, Willey said they adjusted their estimates to reflect the narrative-changing bexobrutideg collaboration with Roche.
Earnings Report
For Q2 2026, Nurix Therapeutics reported:
- EPS of $(0.81), which missed the Zacks Consensus Estimate of $(0.73) and Q2 2025's $(0.52).
- Revenue of $9.04M, which missed the Zacks Consensus Estimate by 36.76% and Q2 2025's $44.06M.
Management did not provide financial gudance in its price target.
President & CEO Arthur T. Sands, M.D., Ph.D., commented: "The second quarter of 2026 was a defining period for Nurix and the targeted protein degradation field.
"Our global collaboration with Roche, an industry leader, validates both the differentiated clinical profile of bexobrutideg in malignant hematology and its broader potential in immunology and inflammation.
"The co-development, co-commercialization structure of the agreement allows Nurix to pursue multiple opportunities in significant markets in both oncology and autoimmune disease with financial strength and global reach."
Jeet Mukherjee, a top 9% analyst from BTIG reiterates NRIX with a strong buy rating and maintains their NRIX price target from $32.00 to $32.00, on Jul 10, 2026.
Gil Blum, a top 3% analyst from Needham reiterates NRIX with a buy rating and maintains their NRIX price target from $34.00 to $34.00, on Jul 10, 2026.
Robert Burns, a top 7% analyst from HC Wainwright & Co. maintains NRIX with a buy rating and raises their NRIX price target from $32.00 to $34.00, on Jul 10, 2026.
Joel Beatty, a top 5% analyst from Baird maintains NRIX with a buy rating and raises their NRIX price target from $26.00 to $33.00, on Jun 18, 2026.
You can dig deeper into what analysts are projecting on the Nurix Therapeutics stock forecast page.
NRIX Trading Indicators
How are NRIX Revenues/Earnings doing?
Last year, NRIX revenue was $36.77M. During the last 5 year, NRIX's revenue has increased by 9.95% per year. This was slower than the Biotechnology industry average of 34.2%.
Learn more about NRIX's earnings and revenue performance here.
Are NRIX executives and large shareholders buying or selling the stock?
Over the past year, insiders at NRIX have sold more shares than they have bought.
Gwenn Hansen, CSci of NRIX, was the latest NRIX insider to sell. They sold $89,954.40 worth of NRIX shares on Jul 30, 2026.
Get more info about who owns NRIX stock here.
Does NRIX provide a stable income stream?
No, Nurix Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about NRIX?
One of the reasons eToro is our favorite brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Place your NRIX purchase
There are two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order enables you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a given dollar amount, use a limit order.
Hit the Open button and eToro will place your order.
If you require additional assistance investing in stocks on eToro, click the how to video below:
Step 6: Get updates on your investment in NRIX
Now that you own some shares in NRIX, you'll want to keep up with your new investment.
Start a watchlist to see the latest developments about your NRIX stock.
NRIX Feed
How to Buy Stock in Nurix Therapeutics
To summarize, here are the 6 steps for buying Nurix Therapeutics stock:
- Decide where to buy Nurix Therapeutics stock
- Create a brokerage account
- Deposit funds into your investment account
- Research Nurix Therapeutics stock
- Place your NRIX purchase
- Get updates on your investment in NRIX
If you need a online brokerage, eToro is our favorite option.
Get Started with eToro TodayIf you want to keep an eye on your investment in Nurix Therapeutics, add NRIX to your watchlist below.
More Content You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.